ReviewSeminars in immunopathology2012
Molecular basis of Staphylococcus epidermidis infections.
Review in Seminars in immunopathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 260 citations in OpenAlex.
- Global distribution, antimicrobial resistance, and virulence factors of Staphylococcus epidermidis revealed through population genomics.BMC genomics · 2026Article
- Host soluble plasma factors increase dual-species Staphylococcus epidermidis and Candida albicans biofilm biomass without enhancing stress tolerance.Scientific reports · 2026Article
- Prevalence of Biofilm-Forming and Antibiotic-Resistant Coagulase-Negative Staphylococci Isolated from Hospitalized Patients in an Orthopedic Clinic.Pathogens (Basel, Switzerland) · 2026Article
- Surface scan cold plasma technology for effective inhibition of Staphylococcus epidermidis and Escherichia coli.Scientific reports · 2026Article
- Comparative genomic analysis of resistance and virulence genes in staphylococcus epidermidis and their impact on clinical outcome of musculoskeletal infections.Scientific reports · 2025Article
- Genome-scale metabolic model ofmSystems · 2025Article
- Prevalence and antimicrobial resistance of gram-positive pathogens in Lebanon: The need for surveillance and stewardship.New microbes and new infections · 2025Article
- Antioxidant-Rich Polyfloral Bee Pollen Exerts Antimicrobial Activity and Anti-Inflammatory Effect in A549 Lung Epithelial Cells by Modulating the NF-κB Pathway.Foods (Basel, Switzerland) · 2025Article
- Identification of bacterial pathogens and antimicrobial susceptibility of early-onset sepsis (EOS) among neonates in Palestinian hospitals: a retrospective observational study.BMC pediatrics · 2025Observational
- Article
- Review
- MIC trends of vancomycin and teicoplanin among methicillin resistant CoNS isolates from new born blood cultures in a tertiary care centre in Southern India.Iranian journal of microbiology · 2024Article
- Completed genome and emergence scenario of the multidrug-resistant nosocomial pathogen Staphylococcus epidermidis ST215.BMC microbiology · 2024Article
- Antibacterial Effect of Spanish Honeys of Different Botanical Origins againstInternational journal of molecular sciences · 2024Article
- InvasiveScience advances · 2023Article
- Biofilms in Periprosthetic Orthopedic Infections Seen through the Eyes of Neutrophils: How Can We Help Neutrophils?International journal of molecular sciences · 2023Review
- Molecular and Phenotypic Characterization of Ocular Methicillin-Resistant Staphylococcus epidermidis Isolates in Taiwan.Investigative ophthalmology & visual science · 2023Article
- Isolation andFrontiers in cellular and infection microbiology · 2023Article
- Mutation of gdpS gene induces a viable but non-culturable state in Staphylococcus epidermidis and changes in the global transcriptional profile.BMC microbiology · 2022Article
- AInsects · 2022Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Staphylococcus epidermidis is the most important member of the coagulase-negative staphylococci and one of the most abundant colonizers of human skin. While for a long time regarded as innocuous, it has been identified as the most frequent cause of device-related infections occurring in the hospital setting and is therefore now recognized as an important opportunistic pathogen. S. epidermidis produces a series of molecules that provide protection from host defenses. Specifically, many proteins and exopolymers, such as the exopolysaccharide PIA, contribute to biofilm formation and inhibit phagocytosis and the activity of human antimicrobial peptides. Furthermore, recent research has identified a family of pro-inflammatory peptides in S. epidermidis, the phenol-soluble modulins (PSMs), which have multiple functions in immune evasion and biofilm development, and may be cytolytic. However, in accordance with the relatively benign relationship that S. epidermidis has with its host, production of aggressive members of the PSM family is kept at a low level. Interestingly, in contrast to S. aureus with its large arsenal of toxins developed for causing infection in the human host, most if not all "virulence factors" of S. epidermidis appear to have original functions in the commensal lifestyle of this bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.